Saturday 17 October 2026
Export EOLS’s income statement to Excel — free account
Evolus, Inc.
EOLS Healthcare Drug Manufacturers Specialty & Generic
Evolus, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $297.2 million, up 11.6% from fiscal 2024. In the quarter to June 2026, revenue grew 21.2%, EPS grew 55.6%, free cash flow grew 84.9% and total debt rose 7.75%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
7.10
0.47
−6.21%
Follow EOLS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.45 | 0.89 | 1.44 | 1.39 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(127.56) | (26.92) | 33.42 | (27.09) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.03 | 1.49 | 2.00 | 2.01 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(41.84) | (12.27) | (14.09) | (11.42) | |
EV/FCF |
(29.39) | (10.01) | (11.74) | (9.91) | |
Quick Ratio |
1.09 | 1.50 | 1.44 | 1.41 | |
Current Ratio |
1.70 | 2.04 | 1.90 | 2.02 | |
Net Debt/EBITDA |
(77.00) | (28.07) | 12.90 | (11.51) | |
Debt/Assets |
63.20% | 70.89% | 64.68% | 66.57% | |
Debt/Equity |
(5.07) | (5.43) | (6.32) | (5.07) | |
Asset Turnover |
1.33 | 1.39 | 1.30 | 1.27 | |
Operating CF/Net income |
0.45 | 0.93 | 98.67 | 0.93 | |
Capex/Depreciation |
(0.16) | (0.55) | (0.74) | (0.82) | |
Interest Coverage |
(1.09) | (1.72) | 1.06 | (2.81) | |
Research and Development Expense of Revenue |
2.25% | 3.06% | 3.85% | 2.97% | |
Selling, General and Administrative Expense of Revenue |
67.85% | 71.07% | 60.53% | 76.58% | |
Intangible Assets out of Total Assets |
0.27 | 0.31 | 0.31 | 0.32 | |
Share Based Compensation of Revenue |
6.69% | 7.00% | 5.70% | 7.45% | |
Graham Net Nets |
(0.24) | (0.41) | (0.25) | (0.28) | |
Graham Number |
2.34 | 2.58 | 2.56 | 3.03 | |
Earnings Yield |
(7.49%) | (16.30%) | (12.18%) | (14.98%) | |
Free Cash Flow Yield |
(4.79%) | (16.75%) | (11.83%) | (14.58%) | |
Revenue per Share |
1.28 | 1.12 | 1.40 | 1.07 | |
Operating CF per Share |
(0.05) | (0.15) | 0.20 | (0.23) | |
Capex per Share |
(0.01) | (0.03) | (0.03) | (0.03) | |
Free Cash Flow per Share |
(0.06) | (0.18) | 0.17 | (0.26) | |
Cash per Share |
0.69 | 0.76 | 0.83 | 0.67 | |
Shareholders Equity per Share |
(0.47) | (0.44) | (0.36) | (0.44) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.47) | (0.44) | (0.36) | (0.44) | |
Free Cash Flow |
(4.09) | (11.64) | 10.66 | (16.83) | |
Working Capital |
68.81 | 70.90 | 67.61 | 68.18 | |
Capital Expenditures |
(0.50) | (1.69) | (2.17) | (2.16) | |
Net Current Asset Value |
(111.38) | (110.50) | (106.06) | (112.87) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.02 | 0.02 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
55.05 | 49.84 | 51.19 | 47.54 | |
Average Payables |
33.90 | 17.85 | 16.30 | 18.40 | |
Average Inventory |
33.68 | 17.41 | 19.56 | 23.88 | |
Average Assets |
238.41 | 217.00 | 229.22 | 224.30 | |
Average Common Equity |
(24.78) | (17.69) | (8.79) | (11.43) |
Columns are period end dates